Downstream biopharmaceutical processing utilises a series of interlocking and sequential operations, including filtration and process chromatography steps, that incrementally increases the purity of the target therapeutic molecule by exploiting the physical and chemical properties of that molecule. Jungmin Oh at Avantor, says that it is critical for therapeutic monoclonal antibodies (mAbs) to have very high purity with low product-related and process-related impurities (host-cell proteins, DNA, leached protein A and aggregates) in order to be administered to patients safely